The Experts below are selected from a list of 1155555 Experts worldwide ranked by ideXlab platform
Kevin K. W. Wang - One of the best experts on this subject based on the ideXlab platform.
-
Biomarkers for Traumatic Brain Injury - Biomarkers for Traumatic Brain Injury
Drug Discovery, 2013Co-Authors: Svetlana A. Dambinova, Ronald L. Hayes, Kevin K. W. WangAbstract:Preface Introduction Medical Need of Biomarkers for TBI The Role of Advanced MRI Findings as Biomarkers of TBI Advances in the Measurement of Mild TBI Neurodegradomics and Biomarkers for Concussions Ionotropic Glutamate Receptors: Preclinical Research Clinical Application of Early Biomarkers for Mild TBI Astroglial Proteins as Biomarkers of Intracerebral Hemorrhage Novel Biomarkers of Combat TBI Utilities of TBI Biomarkers in Various Clinical Settings Economic Impact of Biomarkers on TBI Management TBI Biomarker Assay Development: Future Trends Subject Index
-
Translation of neurological Biomarkers to clinically relevant platforms.
Methods of Molecular Biology, 2009Co-Authors: Ronald L. Hayes, Gillian Robinson, Uwe Müller, Kevin K. W. WangAbstract:Summary Like proteomics more generally, neuroproteomics has recently been linked to the discovery of biochemical markers of central nervous system (CNS) injury and disease. Although neuroproteomics has enjoyed considerable success in discovery of candidate Biomarkers, there are a number of challenges facing inves-tigators interested in developing clinically useful platforms to assess Biomarkers for damage to the CNS. These challenges include intrinsic physiological complications such as the blood–brain barrier. Effective translation of Biomarkers to clinical practice also requires development of entirely novel pathways and product development strategies. Drawing from lessons learned from applications of Biomarkers to traumatic brain injury, this study outlines major elements of such a pathway. As with other indications, Biomarkers can have three major areas of application: (1) drug development; (2) diagnosis and pr ognosis; (3) patient management. Translation of CNS Biomarkers to practical clinical platforms raises a number of integrated elements. Biomarker discovery and initial selection needs to be integrated at the earliest stages with components that will allow systematic prioritization and triage of Biomarker candidates. A number of important criteria need to be considered in selecting clinical Biomarker candidates. Development of proof of concept assays and their optimization and validation represent an often overlooked feature of Biomarker translational research. Initial assay optimization should confirm that assays can detect Biomarkers in relevant clinical samples. Since access to human clinical samples is critical to iden-tification of Biomarkers relevant to injury and disease as well as for assay development, design of human clinical validation studies is an important component of translational Biomarker research platforms. Although these clinical studies share much in common with clinical trials for assessment of drug thera-peutic efficacy, there are a number of considerations unique to these efforts. Finally, platform selection and potential assay commercialization need to be considered. Decisions regarding whether or not to seek FDA approval also significantly influence translational research structures. Key words: Biomarkers , Brain injury , Translational research , Assay development , Clinical trials
Armin Aryannejad - One of the best experts on this subject based on the ideXlab platform.
-
Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review
Neurocritical Care, 2021Co-Authors: Maryam Edalatfar, Seyed Mohammad Piri, Mohammad-mehdi Mehrabinejad, Monireh-sadat Mousavi, Sogol Meknatkhah, Mohammad-reza Fattahi, Zeinab Kavyani, Abdolkarim Hajighadery, Meysam Kaveh, Armin AryannejadAbstract:Emerging evidence suggests that biofluid-based Biomarkers have diagnostic and prognostic potential in traumatic brain injuries (TBI). However, owing to the lack of a conceptual framework or comprehensive review, it is difficult to visualize the breadth of materials that might be available. We conducted a systematic scoping review to map and categorize the evidence regarding biofluid-based biochemical markers of TBI. A comprehensive search was undertaken in January 2019. Of 25,354 records identified through the literature search, 1036 original human studies were included. Five hundred forty biofluid Biomarkers were extracted from included studies and classified into 19 distinct categories. Three categories of Biomarkers including cytokines, coagulation tests, and nerve tissue proteins were investigated more than others and assessed in almost half of the studies (560, 515, and 502 from 1036 studies, respectively). S100 beta as the most common Biomarker for TBI was tested in 21.2% of studies (220 articles). Cortisol was the only Biomarker measured in blood, cerebrospinal fluid, urine, and saliva. The most common sampling time was at admission and within 24 h of injury. The included studies focused mainly on Biomarkers from blood and central nervous system sources, the adult population, and severe and blunt injuries. The most common outcome measures used in studies were changes in Biomarker concentration level, Glasgow coma scale, Glasgow outcome scale, brain computed tomography scan, and mortality rate. Biofluid Biomarkers could be clinically helpful in the diagnosis and prognosis of TBI. However, there was no single definitive Biomarker with accurate characteristics. The present categorization would be a road map to investigate the Biomarkers of the brain injury cascade separately and detect the most representative Biomarker of each category. Also, this comprehensive categorization could provide a guiding framework to design combined panels of multiple Biomarkers.
Alan Maisel - One of the best experts on this subject based on the ideXlab platform.
-
Heart Failure Biomarkers
Journal of Cardiovascular Translational Research, 2013Co-Authors: Rajiv Choudhary, Navaid Iqbal, Fatima Khusro, Erin Higginbotham, Erik Green, Alan MaiselAbstract:Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality research indicating its diagnostic and prognostic capabilities, Biomarkers are excellent adjuncts to manage patients with HF. Their superiority lies mainly in their reflection of ongoing pathophysiological events at a cellular level. Monitoring Biomarker levels has been shown to provide incremental information on the progression of disease, thus allowing to better tailor treatment and management. Several Biomarkers have gained attention in the past decade and continuing research demonstrates the specificity of each Biomarker to be used on its own or in combination to improve diagnostic accuracy. This review will provide an insight into the role of such Biomarkers, which are widely studied in the setting of HF so as to delineate their role in diagnosing, prognosticating, and titrating HF therapy.
Maryam Edalatfar - One of the best experts on this subject based on the ideXlab platform.
-
Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review
Neurocritical Care, 2021Co-Authors: Maryam Edalatfar, Seyed Mohammad Piri, Mohammad-mehdi Mehrabinejad, Monireh-sadat Mousavi, Sogol Meknatkhah, Mohammad-reza Fattahi, Zeinab Kavyani, Abdolkarim Hajighadery, Meysam Kaveh, Armin AryannejadAbstract:Emerging evidence suggests that biofluid-based Biomarkers have diagnostic and prognostic potential in traumatic brain injuries (TBI). However, owing to the lack of a conceptual framework or comprehensive review, it is difficult to visualize the breadth of materials that might be available. We conducted a systematic scoping review to map and categorize the evidence regarding biofluid-based biochemical markers of TBI. A comprehensive search was undertaken in January 2019. Of 25,354 records identified through the literature search, 1036 original human studies were included. Five hundred forty biofluid Biomarkers were extracted from included studies and classified into 19 distinct categories. Three categories of Biomarkers including cytokines, coagulation tests, and nerve tissue proteins were investigated more than others and assessed in almost half of the studies (560, 515, and 502 from 1036 studies, respectively). S100 beta as the most common Biomarker for TBI was tested in 21.2% of studies (220 articles). Cortisol was the only Biomarker measured in blood, cerebrospinal fluid, urine, and saliva. The most common sampling time was at admission and within 24 h of injury. The included studies focused mainly on Biomarkers from blood and central nervous system sources, the adult population, and severe and blunt injuries. The most common outcome measures used in studies were changes in Biomarker concentration level, Glasgow coma scale, Glasgow outcome scale, brain computed tomography scan, and mortality rate. Biofluid Biomarkers could be clinically helpful in the diagnosis and prognosis of TBI. However, there was no single definitive Biomarker with accurate characteristics. The present categorization would be a road map to investigate the Biomarkers of the brain injury cascade separately and detect the most representative Biomarker of each category. Also, this comprehensive categorization could provide a guiding framework to design combined panels of multiple Biomarkers.
Joep Killestein - One of the best experts on this subject based on the ideXlab platform.
-
Body fluid Biomarkers for multiple sclerosis—the long road to clinical application
Nature Reviews Neurology, 2015Co-Authors: Charlotte E. Teunissen, Arjan Malekzadeh, Cyra Leurs, Claire Bridel, Joep KillesteinAbstract:There is a strong unmet clinical need for objective body fluid Biomarkers to assist early diagnosis and estimate long-term prognosis, monitor treatment response and predict potential adverse effects in multiple sclerosis (MS). Here, we review recent studies (focusing on 2012 to early 2015) on body fluid markers in MS from the perspective of their clinical utility. Because the first step towards clinical implementation of a newly discovered Biomarker is independent replication, we focus on Biomarkers that have been validated in at least two independent cohorts. We also discuss recent data challenging earlier findings, and Biomarkers for which new clinical uses are suggested. For early MS diagnosis and prediction of conversion from clinically isolated syndrome to MS, several new B-cell-associated candidate blood Biomarkers have emerged. For prognosis, several novel axonal damage markers should be adopted to Biomarker panels. The number of disease-modifying treatments for MS has increased sharply, but Biomarkers for treatment response monitoring and adverse effect prediction are scarce, and markers for subtyping and staging of MS are still lacking. In view of the availability and implementation of several standardized protocols to optimize Biomarker studies, we expect Biomarker development for MS to be improved and accelerated, with clinical implementation in the near future. Blood and cerebrospinal fluid Biomarkers can assist early diagnosis of multiple sclerosis (MS) and help predict conversion from clinically isolated syndrome to MS Body fluid Biomarkers are also essential in differential diagnosis of neuromyelitis optica Prognostic evaluation of MS is currently challenging, but novel axonal damage markers, including neurofilments and N -acetylaspartate, could be implemented in Biomarker panels to improve their predictive power Despite rapidly increasing number of disease-modifying treatments, few body fluid Biomarkers are available to monitor treatment response and predict adverse effects No clinically implemented Biomarkers are available for MS subtyping and staging; IgM oligoclonal bands and microRNAs are the most promising candidates International collaboration for standardized assays and study protocols, as well as to recruit sufficiently large cohorts, can facilitate Biomarker development The diagnosis and monitoring of multiple sclerosis (MS) still relies largely on clinical manifestations and imaging. Blood-based or cerebrospinal fluid Biomarkers to facilitate prognostic evaluation, staging and subtyping of MS, as well as to predict treatment response and adverse effects, are sorely needed. This comprehensive Review by Charlotte Teunissen and colleagues provides an update on advances in Biomarker development and validation in MS, focusing on the clinical applications of MS Biomarkers.
